Home »
Academic Articles & Research Papers
Showing 17 of 17 academic articles
Ziemska-Legięcka J, Żeber-Lubecka N, Borucka M, Kaczmarska D et al. • Frontiers in immunology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fimmu.2026.1972440
PMC: PMC13733417
Kawazoe T, Tezuka T, Ishizawa K, Matsuki Y et al. • Cancer control : journal of the Moffitt Cancer Center
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.1177/10732748261493412
PMC: PMC13735447
Spindler NJ, Eefsen RL, Persson GF, Nielsen DL et al. • Clinical and translational radiation oncology
(2027)
PMC
PMC Public Access (View-Only)
DOI: 10.1016/j.ctro.2026.101328
PMC: PMC13734791
Liu M, Duan G, Lai X, Lin B et al. • Frontiers in immunology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fimmu.2026.1940260
PMC: PMC13563570
Ostafe MR, Volovat SR, Clement A, Litcanu CI et al. • International journal of molecular sciences
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3390/ijms27177543
PMC: PMC13566291
Jin J, Zheng L, Tian Y, Chu M et al. • Frontiers in medicine
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fmed.2026.1943642
PMC: PMC13579637
Marjanović M, Maletin N, Kukić B, Nikolić I et al. • Frontiers in cellular and infection microbiology
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3389/fcimb.2026.1907957
PMC: PMC13581883
Spessotto P, Orbosuè F, Mongiat M, Maiero S et al. • Nutrients
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3390/nu18183086
PMC: PMC13610758
Cao Y, Zhang Z, Liang Y, Zhao C et al. • Pharmaceuticals (Basel, Switzerland)
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.3390/ph19101616
PMC: PMC13708036
Katja Niesel, Michael Schulz, Julian Anthes, Tijna Alekseeva et al. • EMBO Molecular Medicine
(2021)
Abstract The tumor microenvironment in brain metastases is characterized by high myeloid cell content associated with immune suppressive and cancer‐permissive functions. Moreover, brain metastases induce the recruitment of lymphocytes. Desp...
DOAJ
Open Access (DOAJ)
DOI: 10.15252/emmm.202013412
Safwaan H. Khan, Safwaan H. Khan, Yeonjoo Choi, Mysore Veena et al. • Frontiers in Immunology
(2025)
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies, achieving remarkable clinical success with FDA-approved therapies targeting CD19 and BCMA. However, the extension of these successe...
DOAJ
Open Access (DOAJ)
DOI: 10.3389/fimmu.2024.1489827
Zhen Wang, Honglei Guo, Yanqi Song, Aidi Wang et al. • Frontiers in Immunology
(2025)
Lung cancer is the most common malignant tumor in the world. Presently, there are still problems, including a high recurrence rate, resistance, and serious toxic side effects, even if conventional treatments like chemotherapy, radiotherapy,...
DOAJ
Open Access (DOAJ)
DOI: 10.3389/fimmu.2025.1597686
Mark W. D. Sweep, Mark W. D. Sweep, Martijn J. H. Tjan, Mark A. J. Gorris et al. • Frontiers in Immunology
(2023)
Immune checkpoint inhibitor therapy for cancer treatment can give rise to a variety of adverse events. Here we report a male patient with metastatic melanoma who experienced life-threatening colitis and duodenitis following treatment with i...
DOAJ
Open Access (DOAJ)
DOI: 10.3389/fimmu.2023.1212432
Toshihiro Uemura, Atsunari Kawashima, Kentaro Jingushi, Daisuke Motooka et al. • Scientific Reports
(2026)
Abstract Shotgun metagenomic sequencing provides more detailed microbial information than 16 S rRNA sequencing but requires higher cost and larger sample volumes. We evaluated whether shotgun metagenomic sequencing could detect bacterial DN...
DOAJ
Open Access (DOAJ)
DOI: 10.1038/s41598-026-59896-8
Angel Chao, Ren-Chin Wu, Chiao-Yun Lin, Ting-Chang Chang et al. • Biomedical Journal
(2023)
Small cell neuroendocrine carcinoma of the cervix (SCNECC) is an uncommon but aggressive uterine malignancy, the cause of which is generally associated with human papillomavirus (HPV) infection. A lack of clinical trials and evidence-based ...
DOAJ
Open Access (DOAJ)
DOI: 10.1016/j.bj.2023.100633
Leander van Eekelen, Joey Spronck, Monika Looijen-Salamon, Shoko Vos et al. • Scientific Reports
(2024)
Abstract Programmed death-ligand 1 (PD-L1) expression is currently used in the clinic to assess eligibility for immune-checkpoint inhibitors via the tumor proportion score (TPS), but its efficacy is limited by high interobserver variability...
DOAJ
Open Access (DOAJ)
DOI: 10.1038/s41598-024-57067-1
Fangmin Zhong, Fangyi Yao, Zihao Wang, Bo Huang et al. • npj Precision Oncology
(2025)
Abstract Acute myeloid leukemia (AML) remains challenging due to molecular heterogeneity and limited prognostic models integrating tumor microenvironment dynamics. While thrombocytopenia correlates with poor outcomes, the roles of platelet-...
DOAJ
Open Access (DOAJ)
DOI: 10.1038/s41698-025-01137-8